Bonti is a clinical-stage biotechnology company based in Newport Beach, California focused on developing EB-001, an investigational botulinum neurotoxin serotype E (BoNT/E) with a fast onset and short duration of effect. EB-001 is being developed for targeted therapeutic and aesthetic indications, including post-surgical and non-surgical musculoskeletal pain. The candidate has a rapid onset (within 24 hours) and a shorter duration (about 3–4 weeks) versus marketed BoNT/A products, a profile the company believes suits several clinical uses. Bonti is conducting Phase 2 pain studies (LANTERN-1 ongoing and LANTERN-2 planned) and preparing for an End of Phase 2 FDA meeting. The company announced the appointment of David Ramsay as Chief Financial Officer, effective February 2018. Financially, the Series C brings cumulative investment in Bonti to over $36 million. Bonti is a clinical-stage biotechnology company based in Newport Beach, California, focused on developing EB-001, a botulinum neurotoxin serotype E (BoNT/E) with a differentiated clinical profile. EB-001 has a faster onset of action (about 24 hours) and a shorter duration (about four weeks) compared with marketed BoNT/A products, and is being pursued for both aesthetic and non-surgical and post-surgical therapeutic uses. The company plans to complete a Phase 2 clinical study in the aesthetic indication and to initiate a Phase 2 study for a long-acting, non-opioid musculoskeletal therapeutic in the second half of 2017, with interim data targeted by year-end. Management says proceeds will also propel the company past regulatory steps and enable broader sharing of clinical findings with healthcare professionals. Financially, Bonti has completed a Series A and Series B, bringing cumulative investment to over $20 million to date. The team includes neurotoxin experts with prior experience at Allergan and is positioning EB-001 for multi-billion dollar addressable markets.

Total raised

$27M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2018